about
Nuclear transport of galectin-3 and its therapeutic implicationsGalectin-3 in angiogenesis and metastasis.The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasisAssessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge aheadRacial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer.Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions.Rad6B acts downstream of Wnt signaling to stabilize β-catenin: Implications for a novel Wnt/β-catenin target.miR-21 and miR-145 cooperation in regulation of colon cancer stem cells.Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancerComedo-ductal carcinoma in situ: A paradoxical role for programmed cell deathGalectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers.Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimumOcimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteasesRegulation of prostate cancer progression by galectin-3Metformin: a potential therapeutic agent for recurrent colon cancer.Galectin-3 regulates p21 stability in human prostate cancer cells.Galectins as cancer biomarkers.Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents.Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/MUC1 mediated cancer cellular aggregation.Galectin-3: A novel substrate for c-Abl kinase.Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3.Multivalent scaffolds induce galectin-3 aggregation into nanoparticles.Glycodendrimers and Modified ELISAs: Tools to Elucidate Multivalent Interactions of Galectins 1 and 3.Galectin-3 binding and metastasis.Regulation of tumor progression by extracellular galectin-3.Tamoxifen suppresses histologic progression to atypia and DCIS in MCFIOAT xenografts, a model of early human breast cancer.Galectin-3 and L1 retrotransposons in human breast carcinomas.Galectin-3 binding and metastasis.Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9.Phosphorylated Galectin-3 Mediates Tumor Necrosis Factor-related Apoptosis-inducing Ligand Signaling by Regulating Phosphatase and Tensin Homologue Deleted on Chromosome 10 in Human Breast Carcinoma CellsInhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin
P50
Q26824889-37FDC5F4-7BEB-4695-8861-4FB0A977A3E2Q27687444-E60D1FC7-30F2-424E-97B8-DD61FD93EA31Q28388257-FBBEED35-54DC-48D0-80C0-B2728169DCC8Q28397132-DE977D3C-0C88-4DC0-BE17-ECDAFAAD23EDQ30494804-819F852C-E137-40AA-AAD1-5E8D6F14ED55Q34459046-13F26902-2F83-4CB8-9201-74DBFE429224Q34545405-D916B1B7-5E05-46AD-B14F-E636A25FAA26Q35103483-3A9AF359-796D-4D1E-9E02-2E53BD989F4FQ35179258-1E88522A-2618-4245-A5D8-748A3A03DD7EQ35556332-B79F7BAF-6A77-4D9B-9636-5FCA26EA663CQ35908448-A4BDBA83-C69F-45B2-A44C-FD2476DA2747Q36311531-5DB2B3E6-187C-4395-9CFA-E83AAC46CFA1Q36733651-D240729E-F7A3-4C3C-9D2A-BA8197169CD5Q36733703-13BE328C-619E-478C-B1E0-9AEB3C881853Q36901502-7098B302-BB60-4598-9C18-98042F36E492Q37164578-FD64E20A-B159-4267-9179-134CC79E801EQ37495759-3C8648BD-9F52-4AA2-84CB-C6F3DCBFDE8CQ37542482-DD4CCD76-ACF6-4A6D-9970-0EF2F2C7868BQ38105320-F5B24A4E-780A-4A7F-BCEB-009AF3D6E136Q38290589-66F63B21-123F-4C6F-BC5A-433EB2A22E37Q38304880-70629D0D-6325-4A86-B73B-45AE13D9BA3CQ39684862-91B1EF03-CB6E-4AD1-ACB2-8D10F622116FQ40304129-2787CADB-5F6F-472F-8B38-DD189E2A919BQ41022285-46F237B2-6277-45ED-A39C-CAF54B6B12CDQ41890780-D9B5F62C-FFC3-4BE6-97C3-480E5599542DQ41951811-A7FB296B-15D6-4DED-B862-2CC926BE0419Q42121017-12BDE3DE-AE8D-447F-A5C4-BCE9160CC8C2Q43164816-DDF26F78-2E09-45FF-A745-DFCD8839A1E8Q43540155-D01D5DEC-F4BA-41E6-B064-00B3DC310E97Q47718753-FB7459C6-C766-47A2-A7C5-874D9E024C02Q47769978-9304FF52-CB7A-4383-9937-95D36CC0A5A0Q48077854-9E5DDEFF-547E-4908-A972-E483C1141BD0Q61632642-44CB8E38-4E49-4F4F-A0E0-7B6BFFEF5AF6Q61632645-CE3DC4CA-1FB2-4C03-B090-5A032824D1C1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pratima Nangia-Makker
@ast
Pratima Nangia-Makker
@en
Pratima Nangia-Makker
@es
Pratima Nangia-Makker
@sl
type
label
Pratima Nangia-Makker
@ast
Pratima Nangia-Makker
@en
Pratima Nangia-Makker
@es
Pratima Nangia-Makker
@sl
prefLabel
Pratima Nangia-Makker
@ast
Pratima Nangia-Makker
@en
Pratima Nangia-Makker
@es
Pratima Nangia-Makker
@sl
P106
P21
P31
P496
0000-0002-1917-169X
P569
2000-01-01T00:00:00Z